These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26750639)

  • 1. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
    Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
    Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
    Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
    Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
    Joshi K; Lafeuille MH; Kamstra R; Tiggelaar S; Lefebvre P; Kim E; Yue Y; Tandon N
    J Comp Eff Res; 2018 Feb; 7(2):121-133. PubMed ID: 28809128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.
    Xiao Y; Muser E; Lafeuille MH; Pesa J; Fastenau J; Duh MS; Lefebvre P
    J Comp Eff Res; 2015 Nov; 4(6):579-92. PubMed ID: 26168935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
    Kamstra R; Pilon D; Lefebvre P; Emond B; Joshi K
    Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
    J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
    Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.
    Young-Xu Y; Duh MS; Muser E; DerSarkissian M; Faust E; Kageleiry A; Bhak RH; Fu DJ; Lefebvre P; Shiner B
    J Clin Psychiatry; 2016 Oct; 77(10):e1332-e1341. PubMed ID: 27574835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
    Baser O; Xie L; Pesa J; Durkin M
    J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.
    Pesa JA; Doshi D; Wang L; Yuce H; Baser O
    Curr Med Res Opin; 2017 Apr; 33(4):723-731. PubMed ID: 28044455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.
    Joshi K; Muser E; Xu Y; Schwab P; Datar M; Suehs B
    J Comp Eff Res; 2018 Aug; 7(8):723-735. PubMed ID: 29722547
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
    Patel C; Emond B; Morrison L; Lafeuille MH; Lefebvre P; Lin D; Kim E; Joshi K
    Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.